About NBR“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.
- Delta warns on slowing bookings, higher cash burn as Covid infections climb
- This family bet everything on bitcoin when it was $900 – and bought more when it crashed in 2018
- McConnell says a Covid stimulus compromise is within reach — 'We can do this'
- GOP congressman: New bipartisan Covid stimulus bill in 'range of reason' as momentum shifts to act
- Luminar going public makes 25-year-old Austin Russell one of world's first, and youngest, self-driving billionaires
NBR on TwitterMy Tweets
Subscribe to RSS
Biotech & Pharmaceuticals
Merck & Pfizer raised their guidance and boost their outlooks even as political pressure on the industry ramps up. Meg Tirrell has more for us from the nation’s capital.
Biogen revised its experimental Alzheimer’s drug offering new hope for millions sending its stock to record gains. Meg Tirrell reports.
Biotech stocks surged after Biogen announced plans to revive its Alzheimer’s drug aducanumab.
Purdue Pharma, the maker of OxyContin, the drug widely seen connected to the opioid crisis, has its day in court. Meg Tirrell is at the courthouse for us at White Plains, New York.
Meg Tirrell reports on how Purdue Pharma files for bankruptcy but legal battles are still ahead.
Steve Miller, chairman of Purdue Pharma’s board of directors, told CNBC on Monday that the OxyContin maker’s bankruptcy and tentative deal to resolve opioid lawsuits was the “only way” to get help to victims of the crisis as quickly as possible.
Meg Tirrell reports on the pharmaceutical companies that are in the center of opioid settlement talks.
An Oklahoma judge finds that Johnson & Johnson helped fueled the state’s opioid crisis. Meg Tirrell has more for us from Norman, Oklahoma.
With the recent opioid ruling against Johnson & Johnson, how does this impact the rest of the pharmaceutical industry? Chris Meekins, a Healthcare Policy Analyst at Raymond James, gives us his insights.
Shares of drug distributors fell Tuesday after a report said McKesson, Cardinal Health and AmerisourceBergen have proposed paying $10 billion to settle claims they helped to fuel the U.S. opioid epidemic.
The Trump administration outlined on Wednesday a proposal that would allow the U.S. to legally import cheaper prescription drugs from Canada, a tactic the U.S. pharmaceutical industry and regulators have warned could threaten consumer safety.
Drug maker companies Merck and Eli Lilly posted better than expected results in its quarterly earnings reports. Meg Tirrell takes a closer look at both of these big pharmaceutical firms.
President Donald Trump is working on a proposal that would allow the United States to import drugs from Canada, Health and Human Services Secretary Alex Azar told CNBC.
Pfizer will be merging with its off patent business with Mylan creating a new company that controls a number of blockbuster medicines. Meg Tirrell has more for us on this mega deal.
Pfizer, the world’s largest drugmaker, plans to divest its off-patent drug business and combine it with generic-drug maker Mylan.